Théa is an family owned pharmaceutical company specialized in the research, development and commercialization of eye-care productsThéa is an family owned pharmaceutical company specialized in the research, development and commercialization of eye-care products.
Laboratoires Théa was founded by Henri CHIBRET, a fourth-generation member of a Frenchophthalmological dynasty, born in the nineteenth century. Set up in 1994 from an R & D start-up company, Théa has played an important role in the latest pharmacological advances and in less than 10 years has risen to become the leading independent eye-care group in Europe. Henri and Jean-Fréderic CHIBRET (a fifth generation member of the dynasty) have presided over the group since 2008.
Present in over 65 countries, particularly in Europe, North and Sub Saharan Africa, South America and the Middle East,
Contact
Mariahilfer Str. 103/Stiege 3/Top 521060 Wien
Tel +43 1 595 40 49 0
Website www.thea-pharma.at
Email office@thea-pharma.at
Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa…
With revenues projected to reach USD 27.01 billion in 2024, France’s pharma market is ranked fifth globally. Home to a number of well-established local pharma players and a sought-after destination…
France’s life sciences industry is falling behind its European neighbours, its growth deeply hampered, the French life sciences think tank G5 Santé claims, by abusive paybacks. While the government has…
Encircled by heavyweight life sciences powerhouses of the likes of Germany, France and Switzerland, plucky Belgium nonetheless continues to astonish and project considerable influence when it comes to its abilities…
Théa veteran and GM of the French ophthalmology midcap’s BeLux affiliate, Ivan Perrichon, reveals the company’s plans to pursue its growth trajectory, launch ten new products in Belgium and reach…
Ana Fernández of Théa Spain discusses the strategic importance of the Spanish affiliate – the group’s oldest, current trends in Spanish ophthalmology, and what differentiates Théa – as a family-run…
Philip Lews Williams, managing director of the UK affiliate of French ophthalmology specialist Théa, describes the evolution of the company’s engagement in the UK and his strategy for taking on…
Several smaller pharmaceutical companies – Taiho, Valneva, Mallinckrodt, Théa and Intercept Pharma – have chosen to set up operations in Canada very recently, recognizing the potential for product launches and development…
Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the…
Mark Smithyes, president of Labtician Théa, highlights the company’s ambition to become the leader and preferred partner to optometrists and ophthalmologists in Canada by launching products from Laboratoires Théa’s innovative…
Günther Aschenbrenner, managing director of Théa Austria, a specialist French ophthalmology company, discusses the development of the company’s Austrian office since 2011 and how a strong portfolio acquired by Théa…
Austria has long been merely a cog in the wheel of global R&D, lying in the shadows of neighboring research giants, Germany and Switzerland. Now, however, this perception is changing…
Peter Tsai, founder, CEO, and chairman of Orient EuroPharma (OEP), one of the leading groups of healthcare companies in Taiwan, provides insights into his strategic vision to double the group’s…
See our Cookie Privacy Policy Here
